Literature DB >> 1901826

Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome.

P J Wilson1, G K Suthers, D F Callen, E Baker, P V Nelson, A Cooper, J E Wraith, G R Sutherland, C P Morris, J J Hopwood.   

Abstract

Hunter syndrome is a human X-linked disorder caused by deficiency of the lysosomal exohydrolase iduronate-2-sulphatase (IDS). The consequent accumulation of the mucopolysaccharides dermatan sulphate and heparan sulphate, in the brain and other tissues, often results in death before adulthood. There is, however, a broad spectrum of severity that has been attributed to different mutations of the Hunter syndrome gene. We have used an IDS cDNA clone to localise the IDS gene to Xq28, distal to the fragile X mutation (FRAXA). One-third of Hunter syndrome patients had various deletions or rearrangements of their IDS gene, proving that different mutations are common in this condition. Deletions of the IDS gene can include a conserved locus that is tightly linked to FRAXA, suggesting that deletion of nearby genes may contribute to the variable clinical severity noted in Hunter syndrome. The cDNA clone was also shown to span the X chromosome breakpoint in a female Hunter syndrome patient with an X;autosome translocation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901826     DOI: 10.1007/bf00194643

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  13 in total

Review 1.  The mucopolysaccharidoses. Diagnosis, molecular genetics and treatment.

Authors:  J J Hopwood; C P Morris
Journal:  Mol Biol Med       Date:  1990-10

2.  A new DNA marker tightly linked to the fragile X locus (FRAXA).

Authors:  G K Suthers; D F Callen; V J Hyland; H M Kozman; E Baker; H Eyre; P S Harper; S H Roberts; M C Hors-Cayla; K E Davies
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

3.  Localization of the human G-CSF gene to the region of a breakpoint in the translocation typical of acute promyelocytic leukemia.

Authors:  R N Simmers; J Smith; M F Shannon; G Wong; A F Lopez; E Baker; G R Sutherland; M A Vadas
Journal:  Hum Genet       Date:  1988-02       Impact factor: 4.132

4.  Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties.

Authors:  J Bielicki; C Freeman; P R Clements; J J Hopwood
Journal:  Biochem J       Date:  1990-10-01       Impact factor: 3.857

5.  Enzymatic diagnosis of the mucopolysaccharidoses: experience of 96 cases diagnosed in a five-year period.

Authors:  J J Hopwood; V Muller; J R Harrison; W F Carey; H Elliott; E F Robertson; A C Pollard
Journal:  Med J Aust       Date:  1982-03-20       Impact factor: 7.738

6.  An assay for iduronate sulfatase (Hunter corrective factor).

Authors:  T W Lim; I G Leder; G Bach; E F Neufeld
Journal:  Carbohydr Res       Date:  1974-10       Impact factor: 2.104

7.  alpha-L-iduronidase, beta-D-glucuronidase, and 2-sulfo-L-iduronate 2-sulfatase: preparation and characterization of radioactive substrates from heparin.

Authors:  J J Hopwood
Journal:  Carbohydr Res       Date:  1979-03       Impact factor: 2.104

8.  Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA.

Authors:  P J Wilson; C P Morris; D S Anson; T Occhiodoro; J Bielicki; P R Clements; J J Hopwood
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

9.  Cystic fibrosis: prenatal diagnosis and carrier detection by DNA analysis.

Authors:  P V Nelson; W F Carey; C P Morris; A C Pollard
Journal:  Med J Aust       Date:  1989-08-07       Impact factor: 7.738

10.  Chromosomal localization of the gene for human glucosamine-6-sulphatase to 12q14.

Authors:  D A Robertson; D F Callen; E G Baker; C P Morris; J J Hopwood
Journal:  Hum Genet       Date:  1988-06       Impact factor: 4.132

View more
  22 in total

1.  Gene diagnosis and carrier detection in Hunter syndrome by the iduronate-2-sulphatase cDNA probe.

Authors:  A Gal; M Beck; A C Sewell; C P Morris; E Schwinger; J J Hopwood
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Characterization of a deletion at Xq27-q28 associated with unbalanced inactivation of the nonmutant X chromosome.

Authors:  J T Clarke; P J Wilson; C P Morris; J J Hopwood; R I Richards; G R Sutherland; P N Ray
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

3.  Germline and somatic mosaicism in a female carrier of Hunter disease.

Authors:  R Froissart; I Maire; V Bonnet; T Levade; D Bozon
Journal:  J Med Genet       Date:  1997-02       Impact factor: 6.318

4.  Long-term follow-up following bone marrow transplantation for Hunter disease.

Authors:  A Vellodi; E Young; A Cooper; V Lidchi; B Winchester; J E Wraith
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

5.  Molecular analysis in patients with mucopolysaccharidosis type II suggests that DXS466 maps within the Hunter gene.

Authors:  C Steglich; S Bunge; T Hulsebos; M Beck; N J Brandt; E Schwinger; J J Hopwood; A Gal
Journal:  Hum Genet       Date:  1993-09       Impact factor: 4.132

6.  Structural gene aberrations in mucopolysaccharidosis II (Hunter).

Authors:  M Wehnert; J J Hopwood; W Schröder; F H Herrmann
Journal:  Hum Genet       Date:  1992-06       Impact factor: 4.132

7.  Heterogeneity of DNA and RNA in Hunter patients.

Authors:  T Annella; A Daniele; P Di Natale
Journal:  Hum Genet       Date:  1993-10       Impact factor: 4.132

8.  The clinical phenotype of two patients with a complete deletion of the iduronate-2-sulphatase gene (mucopolysaccharidosis II--Hunter syndrome).

Authors:  J E Wraith; A Cooper; M Thornley; P J Wilson; P V Nelson; C P Morris; J J Hopwood
Journal:  Hum Genet       Date:  1991-06       Impact factor: 4.132

9.  MRI in the mild type of mucopolysaccharidosis II (Hunter's syndrome).

Authors:  N Shinomiya; T Nagayama; Y Fujioka; T Aoki
Journal:  Neuroradiology       Date:  1996-07       Impact factor: 2.804

10.  Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease).

Authors:  E Vafiadaki; A Cooper; L E Heptinstall; C E Hatton; M Thornley; J E Wraith
Journal:  Arch Dis Child       Date:  1998-09       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.